Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin

Inclusion Criteria: * 30\~32nd weeks pregnant women aged over 18 years * Women who have Hb level of more than 10.0g/dL a week before study initiation * Patients who agree to participate in this study in writing Exclusion Criteria: * Patients who have participated in another clinical study in recent 3 months * Patients who are prone to acute hemorrhage during pregnancy * Patients who have shown intolerance to iron therapy * Hemolytic anemia, hemoglobinopathies (thalassemia, sickle cell) * Bleeding tendency, hypersplenism * Chronic heart failure, Class II-IV heart disease, uncontrolled arterial hypertension (DBP ≥ 115mmHg), deep vein thrombosis, thrombocytosis, chronic renal disease * Severe renal failure patients (2.5 times or more higher plasma creatinine level than high limit of normal state) * Patients with severe liver dysfunction (2.5 times or more higher AST or ALT than high limit of normal state) * Patients with doubled or more CK level than high limit of normal state * Patients who are regarded as ineligible for this study by investigator